GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (LTS:0L85) » Definitions » EV-to-FCF

Sorrento Therapeutics (LTS:0L85) EV-to-FCF : -0.55 (As of May. 12, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Sorrento Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sorrento Therapeutics's Enterprise Value is $134.41 Mil. Sorrento Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was $-243.21 Mil. Therefore, Sorrento Therapeutics's EV-to-FCF for today is -0.55.

The historical rank and industry rank for Sorrento Therapeutics's EV-to-FCF or its related term are showing as below:

LTS:0L85' s EV-to-FCF Range Over the Past 10 Years
Min: -37.85   Med: -3.76   Max: -0.55
Current: -0.55

During the past 13 years, the highest EV-to-FCF of Sorrento Therapeutics was -0.55. The lowest was -37.85. And the median was -3.76.

LTS:0L85's EV-to-FCF is ranked worse than
100% of 390 companies
in the Biotechnology industry
Industry Median: 6.365 vs LTS:0L85: -0.55

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Sorrento Therapeutics's stock price is $0.015. Sorrento Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.120. Therefore, Sorrento Therapeutics's PE Ratio for today is At Loss.


Sorrento Therapeutics EV-to-FCF Historical Data

The historical data trend for Sorrento Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics EV-to-FCF Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.98 -4.28 -11.85 -5.41 -1.75

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.90 -2.54 -1.75 -1.16 -1.36

Competitive Comparison of Sorrento Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Sorrento Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sorrento Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's EV-to-FCF falls into.



Sorrento Therapeutics EV-to-FCF Calculation

Sorrento Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=134.407/-243.212
=-0.55

Sorrento Therapeutics's current Enterprise Value is $134.41 Mil.
Sorrento Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-243.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sorrento Therapeutics  (LTS:0L85) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sorrento Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.015/-1.120
=At Loss

Sorrento Therapeutics's share price for today is $0.015.
Sorrento Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.120.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Sorrento Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sorrento Therapeutics (LTS:0L85) Business Description

Traded in Other Exchanges
Address
4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Sorrento Therapeutics (LTS:0L85) Headlines

No Headlines